An open‐label study of the safety and tolerability of converting stable liver transplant recipients to neoral
Tousif M. Pasha, Russell H. Wiesner, Linda M. Dahlke, Michael K. Porayko, Ruud A.F. Krom – 30 December 2003 – Neoral is a new formulation of cyclosporine based on microemulsion technology, designed to provide increased and more reliable absorption of the medication. The aim of this study was to assess whether conversion from Sandimmune to Neoral provides safe and effective oral immunosuppression in stable liver transplant recipients. We studied 59 stable liver transplant recipients (being treated with prednisone, azathioprine, and Sandimmune).